Navigation Links
Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance
Date:3/12/2010

SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), today reported recent accomplishments, announced fourth quarter and full-year 2009 financial results and provided key upcoming clinical development milestones and financial guidance for 2010.

"Having already confirmed RDEA594's single-agent potential and demonstrated its additive activity when administered in combination with allopurinol or febuxostat, the two most widely prescribed current gout medications, we eagerly await the results from our Phase 2b program," commented Barry D. Quart, Pharm.D., president and chief executive officer.  "We believe the results from our two Phase 2b studies, expected over the next few months, will confirm the broad clinical utility of RDEA594 and provide the basis for initiating a Phase 3 development program in the second half of 2010."

Recent Accomplishments

  • In

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Research and Markets  has ... Neurotechnology: 2014-2018" report to their offering. ... most comprehensive and up-to-date publication available covering the neurotechnology ... technology, markets, competitors, and growth rates in four key ... through 2018. It forecasts the number of systems to ...
(Date:9/22/2014)... Sept. 22, 2014 Research and Markets ... and Other Novel Hypercholesterolemia Drugs" report to their ... is a high cholesterol burden despite the presence of ... the available options, statins have been ubiquitously prescribed over ... of plasma LDL cholesterol (LDLC) is the cornerstone of ...
(Date:9/22/2014)... , September 22, 2014 Persistence ... on "Global Market Study on Ophthalmic Devices: ... the global ophthalmic devices market was valued at USD 29,171.5 million ... CAGR of 6.5% from 2014 to 2020, to reach ... Browse the full Global Market Study on Ophthalmic ...
Breaking Medicine Technology:The Market for Neurotechnology: 2014-2018 2PCSK9 and Other Novel Hypercholesterolemia Drugs 2PCSK9 and Other Novel Hypercholesterolemia Drugs 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5
... , COCKEYSVILLE, Maryland, November 2 ... Iron Phosphate Technology,to New Levels. , ... high-tech,batteries for industry, has expanded its range of lithium technologies ... phosphate,cell on the market. These large cells are designed for ...
... Shire plc (LSE: SHP, Nasdaq: SHPGY ... a major medical meeting from a Phase IIIb study of ... (methylphenidate transdermal system) in adolescents aged 13 to 17 years ... In addition, data regarding the pharmacokinetic profile of Daytrana in ...
Cached Medicine Technology:Saft Develops Super-Phosphate(TM) Technology for Rigorous Defense Applications 2Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 2Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 3Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 4Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 5Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 6Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 7
(Date:9/22/2014)... South Asians living in Canada have a higher rate ... compared with while people, McMaster researchers have found. ... Canadian Medical Association Journal (CMAJ Open) and may ... the fastest-growing ethnic groups in the country is the ... Canada, comprising about three percent of the population. They ...
(Date:9/22/2014)... -- Recent two-generation approaches to reducing poverty that ... attention from researchers, advocates, and foundations. By combining ... to move to jobs that offer a path ... education for children, these programs aim to improve ... to a new report from the National Center ...
(Date:9/22/2014)... UK (PRWEB) September 22, 2014 The ... in the recent years. The statistically important data received ... safety of cancer vaccines. The primary challenge to the ... information about the exact mechanism of how a human’s ... to various results in different individuals owing to known ...
(Date:9/22/2014)... MONDAY, Sept. 22, 2014 (HealthDay News) -- Scans ... they learn to read. This finding could potentially ... other reading difficulties early on, preliminary research suggests. ... in children with dyslexia as well as most ... Hoeft, an associate professor of child and adolescent ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 CareFlight ... has taken delivery of a new AS365 N3+ Dauphin, ... helicopter. The new aircraft, which is based at ... all-Dauphin fleet of four air medical transport helicopters. , ... said Candy Skidmore, Premier Health Vice President, Emergency, Trauma, ...
Breaking Medicine News(10 mins):Health News:Higher risk of heart disease for South Asians in Canada 2Health News:A two-generation lens: Current state policies fail to support families with young children 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3
... 24 Catholic Charities,USA today urged Congress and ... come together to pass a comprehensive children,s health,insurance ... to vote on a compromise bill to,reauthorize the ... program that provides health insurance coverage to poor,children. ...
... and S.E.VEN, BOSTON, Sept. 24 Small Army, ... a cure for diabetes and,alleviating world poverty to their ... and S.E.VEN. "As communicators, we welcome the challenge ... dollars, but by a commitment,to truly make the world ...
... to Execute and Completeness of Vision, ANDOVER, ... management (IAM) solutions are the most widely implemented ... in the Visionaries,quadrant by Gartner, Inc. in the ... of the Magic Quadrant for User Provisioning, 2H07,(authored ...
... a,leading technology provider of mobile enterprise solutions for ... NASDAQ Stock,Market LLC has approved its application for ... Capital Market. Trading in the Company,s common stock,commenced ... the symbol "IFLG." (Logo: http://www.newscom.com/cgi-bin/prnh/20060209/PHTH052LOGO ...
... CHASKA, Minn., Sept. 24 Tired? Stressed? ... restore, and rejuvenate? The Village Company,( http://www.thevillagecompany.com ... bath,and body products, announces the nationwide launch ... relief from common ailments,( http://www.thevillagecompany.com/vntherapy.html ). ...
... Novo Nordisk, a,world leader in diabetes care, ... the Dow Jones Sustainability World Index (DJSI World) ... 18 global supersectors,analyzed. The latest global analysis ... analysis of companies, economic, environmental and,social performance, assessing ...
Cached Medicine News:Health News:Catholic Charities USA Calls on Congress and the President to Protect the Health of Children; Urges President Not to Veto Vitally Important Bill 2Health News:Catholic Charities USA Calls on Congress and the President to Protect the Health of Children; Urges President Not to Veto Vitally Important Bill 3Health News:Small Army Takes on Cure for Diabetes and New Approach to Ending World Poverty with Addition of Non-Profit Accounts 2Health News:Sentillion Positioned in Visionaries Quadrant in Leading Industry Analyst Firm's User Provisioning Magic Quadrant 2Health News:Sentillion Positioned in Visionaries Quadrant in Leading Industry Analyst Firm's User Provisioning Magic Quadrant 3Health News:InfoLogix Announces Approval for NASDAQ Listing 2Health News:InfoLogix Announces Approval for NASDAQ Listing 3Health News:The Village Company Unveils Natural Bath and Body Solutions for Everyday Ailments 2Health News:Novo Nordisk Ranks Supersector Leader in the 2007 Dow Jones Sustainability Indexes 2
... of fibre bronchoscopy: The HF-compatible V series ... other fibre bronchoscopes are measured., ,The ... including the FB-19TV, FB-18V and FB-15V models ... the pediatric FB-8V, offer much better image ...
... High performance fiberoptic imaging from ... ,Olympus has improved its fiberscope range, ... specifications and enhanced image performance. Olympus ... instruments for diagnosis and therapy in ...
... performance fiberoptic imaging from the latest ... improved its fiberscope range, focussing on ... enhanced image performance. Olympus has a ... diagnosis and therapy in the respiratory ...
Slim bronchoscope designed for paediatric applications....
Medicine Products: